ChaachouayNZidaneL (2024) Correction: Chaachouay, N.; zidane, L. Plant-derived natural products: A source for drug discovery and development. Drugs Drug Candidates3: 184–207.
2.
HoughtonDShannonOMChaterPI, et al. (2023) White kidney bean extract as a nutraceutical: Effects on gut microbiota, alpha-amylase inhibition, and user experiences. Gut Microbiome (Cambridge, England)4: e8.
3.
HusakVShvadchakVBobrovaO, et al. (2026) Plant-derived strategies for glycemic management in diabetes: A narrative review. Diabetology7(2): 29.
4.
JägerRAbou SawanSPurpuraM, et al. (2024) Proprietary alpha-amylase inhibitor formulation from white kidney bean (Phaseolus vulgaris L.) promotes weight and fat loss: A 12-week, double-blind, placebo-controlled, randomized trial. Scientific Reports14(1): 12685.
5.
MuzaffarHJehangirMHuJ, et al. (2025) Therapeutic potential of white kidney beans (Phaseolus vulgaris) for weight management. Foods (Basel, Switzerland)14(22): 3940.
6.
NolanRShannonOMRobinsonN, et al. (2020) It's no has bean: A review of the effects of white kidney bean extract on body composition and metabolic health. Nutrients12(5): 1398.
7.
OnakpoyaIAldaasSTerryR, et al. (2011) The efficacy of Phaseolus vulgaris as a weight-loss supplement: A systematic review and meta-analysis of randomised clinical trials. The British Journal of Nutrition106(2): 196–202.
8.
PeddioSPadigliaACanneaFB, et al. (2022) Common bean (Phaseolus vulgaris L.) α-amylase inhibitors as safe nutraceutical strategy against diabetes and obesity: An update review. Phytotherapy Research36(7): 2803–2823.
9.
SantiniANovellinoE (2018) Nutraceuticals - shedding light on the grey area between pharmaceuticals and food. Expert Review of Clinical Pharmacology11(6): 545–547.
10.
UdaniJTanOMolinaJ (2018) Systematic review and meta-analysis of a proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris L.) on weight and fat loss in humans. Foods (Basel, Switzerland)7(4): 63.
